Lunai Bioworks

Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. Founded on January 18, 2011, by Rene Sindlev and Serhat Gumrukcu, Lunai Bioworks maintains its corporate base in Los Angeles, California.